We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy
This peptide from the Spike (S) protein of SARS-CoV is a naturally processed epitope shown to induce specific CTLs. The peptide epitope was validated in binding assay to HLA-A2 of T2 cell line. It also induced specific CD8+ T-cell responses against SARS-CoV. This peptide sequence is also seen within the spike glycoprotein of SARS-CoV2.
Peptide Library Construction and Screening
Powerful screening tools in biological and chemical research
Sequence | One Letter Code: VLNDILSRL Three-Letter Code: H-Val-Leu-Asn-Asp-Ile-Leu-Ser-Arg-Leu-OH |
Purity | % Peak Area By HPLC ≥ 95% |
Size | 1 mg NET peptide |
References | 1. Lv Y, et al. Identification of a novel conserved HLA-A* 0201-restricted epitope from the spike protein of SARS-CoV. BMC immunology. 2009 Dec 1;10(1):61.2. Grifoni A et al. A sequence homology and bioinformatic approach can predict candidate targets for immune responses to SARS-CoV-2. Cell host & microbe. 2020 Mar 16.3. Ahmed SF et al. Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses. 2020 Mar;12(3):254. |
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at info@creative-peptides.com. We will endeavor to provide highly satisfying products and services.
USA
Address: SUITE 115, 17 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-624-4882
Fax: 1-631-614-7828
Email: info@creative-peptides.com
Germany
Address: Industriepark Höchst, Gebäude G830
65929 Frankfurt am Main
Email: info@creative-peptides.com